Objective Heart failure (HF) is a major public health issue due to its high morbidity, mortality and healthcare burden. This ...
Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO. Efficacy and safety ...
New clinical score predicts laryngeal involvement in pemphigus vulgaris, helping reduce unnecessary procedures while identifying high risk patients.
Treatment patterns, attrition, and survival outcomes in patients with metastatic unclassified renal cell carcinoma. Median PFS (months, 95% CI) 5.7 (3.8-8.7) 5.6 (3.9-7) 12-month PFS rate (%, 95% CI) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results